Synthesis, biological evaluation and molecular docking studies of 2-piperazin-1-yl-quinazolines as platelet aggregation inhibitors and ligands of integrin αIIbβ3 was written by Krysko, Andrei A.;Kornylov, Alexander Yu.;Polishchuk, Pavel G.;Samoylenko, Georgiy V.;Krysko, Olga L.;Kabanova, Tatyana A.;Kravtsov, Victor Ch.;Kabanov, Vladimir M.;Wicher, Barbara;Andronati, Sergei A.. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2016.Reference of 162046-66-4 This article mentions the following:
A series of 2-piperazin-1-yl-quinazolines were synthesized and evaluated for their antiaggregative activity. The synthesized small mol. compounds have potently inhibited platelet aggregation in vitro and blocked FITC-Fg binding to αIIbβ3 integrin in a suspension of washed human platelets. The key αIIbβ3 protein-ligand interactions were determined in docking experiments and some correlations have been observed between values of the affinity and docking scores. In the experiment, the researchers used many compounds, for example, 4-(4-(tert-Butoxycarbonyl)piperazin-1-yl)benzoic acid (cas: 162046-66-4Reference of 162046-66-4).
4-(4-(tert-Butoxycarbonyl)piperazin-1-yl)benzoic acid (cas: 162046-66-4) belongs to piperazine derivatives. Simple N-substituted piperazines have been found in many drug molecules. Piperazine and its salts did not induce point mutations in a bacterial test. A series of mutagenicity studies in cells, both in vitro and in vivo, has been completed and showed no evidence of mutagenic effect.Reference of 162046-66-4
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics